Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Completed · Phase 3 · Has a placebo group

Conditions studied: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic

In brief

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

Key facts

Study ID
NCT06439602
Run by
Arthrosi Therapeutics
People needed
818
Starts
2024-06-26
Expected to finish
2026-04-10
Last updated by the study team
2026-05-13

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.